vs

Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and PureCycle Technologies, Inc. (PCT). Click either name above to swap in a different company.

MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $2.7M, roughly 1.8× PureCycle Technologies, Inc.). MAXCYTE, INC. runs the higher net margin — -200.5% vs -697.1%, a 496.6% gap on every dollar of revenue. MAXCYTE, INC. produced more free cash flow last quarter ($-2.9M vs $-42.0M).

MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.

PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.

MXCT vs PCT — Head-to-Head

Bigger by revenue
MXCT
MXCT
1.8× larger
MXCT
$4.8M
$2.7M
PCT
Higher net margin
MXCT
MXCT
496.6% more per $
MXCT
-200.5%
-697.1%
PCT
More free cash flow
MXCT
MXCT
$39.1M more FCF
MXCT
$-2.9M
$-42.0M
PCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MXCT
MXCT
PCT
PCT
Revenue
$4.8M
$2.7M
Net Profit
$-9.6M
$-18.8M
Gross Margin
Operating Margin
-234.5%
-2196.1%
Net Margin
-200.5%
-697.1%
Revenue YoY
-20.9%
Net Profit YoY
9.4%
71.0%
EPS (diluted)
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MXCT
MXCT
PCT
PCT
Q4 25
$4.8M
$2.7M
Q3 25
$4.6M
$2.4M
Q2 25
$5.8M
$1.6M
Q1 25
$5.7M
$1.6M
Q4 24
$6.1M
$0
Q3 24
$5.6M
$0
Q2 24
$5.0M
$0
Q1 24
$5.6M
$0
Net Profit
MXCT
MXCT
PCT
PCT
Q4 25
$-9.6M
$-18.8M
Q3 25
$-12.4M
$-28.4M
Q2 25
$-12.4M
$-144.2M
Q1 25
$-10.3M
$8.8M
Q4 24
$-10.6M
$-64.7M
Q3 24
$-11.6M
$-90.6M
Q2 24
$-9.4M
$-48.2M
Q1 24
$-9.5M
$-85.6M
Operating Margin
MXCT
MXCT
PCT
PCT
Q4 25
-234.5%
-2196.1%
Q3 25
-307.4%
-1602.2%
Q2 25
-244.3%
-2763.5%
Q1 25
-214.1%
-2387.4%
Q4 24
-213.1%
Q3 24
-250.4%
Q2 24
-241.0%
Q1 24
-219.8%
Net Margin
MXCT
MXCT
PCT
PCT
Q4 25
-200.5%
-697.1%
Q3 25
-269.7%
-1167.5%
Q2 25
-212.2%
-8741.8%
Q1 25
-178.7%
559.0%
Q4 24
-175.0%
Q3 24
-205.9%
Q2 24
-188.8%
Q1 24
-170.6%
EPS (diluted)
MXCT
MXCT
PCT
PCT
Q4 25
$-0.14
Q3 25
$-0.12
$-0.31
Q2 25
$-0.12
$-0.81
Q1 25
$0.05
Q4 24
$-0.40
Q3 24
$-0.11
$-0.54
Q2 24
$-0.09
$-0.29
Q1 24
$-0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MXCT
MXCT
PCT
PCT
Cash + ST InvestmentsLiquidity on hand
$103.0M
$156.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$171.5M
$45.9M
Total Assets
$202.5M
$922.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MXCT
MXCT
PCT
PCT
Q4 25
$103.0M
$156.7M
Q3 25
$105.7M
$234.4M
Q2 25
$126.6M
$284.1M
Q1 25
$138.3M
$22.5M
Q4 24
$154.5M
$15.7M
Q3 24
$153.8M
$83.7M
Q2 24
$157.3M
$10.9M
Q1 24
$157.5M
$25.0M
Stockholders' Equity
MXCT
MXCT
PCT
PCT
Q4 25
$171.5M
$45.9M
Q3 25
$180.3M
$68.2M
Q2 25
$190.7M
$98.9M
Q1 25
$199.4M
$238.2M
Q4 24
$206.3M
$180.4M
Q3 24
$213.3M
$241.4M
Q2 24
$221.3M
$291.6M
Q1 24
$226.4M
$336.8M
Total Assets
MXCT
MXCT
PCT
PCT
Q4 25
$202.5M
$922.7M
Q3 25
$213.5M
$989.1M
Q2 25
$219.8M
$1.0B
Q1 25
$230.0M
$787.3M
Q4 24
$239.5M
$798.4M
Q3 24
$248.6M
$788.8M
Q2 24
$251.5M
$719.8M
Q1 24
$257.9M
$734.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MXCT
MXCT
PCT
PCT
Operating Cash FlowLast quarter
$-2.7M
$-28.7M
Free Cash FlowOCF − Capex
$-2.9M
$-42.0M
FCF MarginFCF / Revenue
-61.0%
-1559.6%
Capex IntensityCapex / Revenue
4.8%
495.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-36.2M
$-183.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MXCT
MXCT
PCT
PCT
Q4 25
$-2.7M
$-28.7M
Q3 25
$-7.5M
$-38.5M
Q2 25
$-9.9M
$-36.7M
Q1 25
$-14.4M
$-38.9M
Q4 24
$-7.8M
$-31.8M
Q3 24
$-4.4M
$-33.4M
Q2 24
$-4.8M
$-40.4M
Q1 24
$-10.6M
$-39.2M
Free Cash Flow
MXCT
MXCT
PCT
PCT
Q4 25
$-2.9M
$-42.0M
Q3 25
$-7.8M
$-42.4M
Q2 25
$-10.4M
$-45.3M
Q1 25
$-15.1M
$-53.9M
Q4 24
$-8.0M
$-53.4M
Q3 24
$-4.8M
$-42.6M
Q2 24
$-5.1M
$-50.8M
Q1 24
$-11.4M
$-53.5M
FCF Margin
MXCT
MXCT
PCT
PCT
Q4 25
-61.0%
-1559.6%
Q3 25
-168.5%
-1743.1%
Q2 25
-179.2%
-2747.1%
Q1 25
-262.3%
-3409.6%
Q4 24
-131.6%
Q3 24
-85.5%
Q2 24
-103.3%
Q1 24
-203.6%
Capex Intensity
MXCT
MXCT
PCT
PCT
Q4 25
4.8%
495.1%
Q3 25
6.5%
160.3%
Q2 25
10.0%
521.5%
Q1 25
11.4%
949.6%
Q4 24
2.4%
Q3 24
7.2%
Q2 24
5.9%
Q1 24
14.4%
Cash Conversion
MXCT
MXCT
PCT
PCT
Q4 25
Q3 25
Q2 25
Q1 25
-4.40×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MXCT
MXCT

Products$4.2M87%
Other$634.0K13%

PCT
PCT

Segment breakdown not available.

Related Comparisons